Sanofi (SNY)
| Market Cap | 102.43B -21.5% |
| Revenue (ttm) | 54.60B +4.8% |
| Net Income | 8.71B +19.9% |
| EPS | 7.15 +23.0% |
| Shares Out | 1.20B |
| PE Ratio | 11.76 |
| Forward PE | 8.54 |
| Dividend | $1.76 (4.00%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 1,491,554 |
| Open | 44.19 |
| Previous Close | 42.37 |
| Day's Range | 44.17 - 44.60 |
| 52-Week Range | 42.28 - 52.68 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 55.90 (+26.61%) |
| Earnings Date | Apr 23, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $55.9, which is an increase of 26.61% from the latest price.
News
Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.
Sanofi Transcript: Jefferies Global Healthcare Conference 2026
Immunology and vaccines divisions are advancing robust pipelines, with multiple phase III starts and key data readouts expected in the next year. Strategic focus includes expanding RSV and combination vaccines, adapting to digital and regulatory shifts, and leveraging BD to fill portfolio gaps.
Sanofi (SNY) Unveils AI-Driven Sales Support Tool
Sanofi (SNY) Unveils AI-Driven Sales Support Tool
Snowflake says Sanofi selects Snowflake Cortex AI for drug development
Snowflake (SNOW) announced at Snowflake Summit 26 that Sanofi (SNY) has established a new blueprint for AI-powered biopharma with its launch of “Concierge for Field,” a new AI agent built…
Sanofi (SNY) Receives FDA Priority Review for Venglustat Application
Sanofi (SNY) Receives FDA Priority Review for Venglustat Application
Sanofi announces FDA grants priority review to venglustat new drug application
The FDA has granted priority review to Sanofi’s (SNY) new drug application for venglustat, an investigational oral glucosylceramide synthase inhibitor, for the treatment of type 3 Gaucher disease, a r...
Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug ap...
Sanofi is building its own AI ecosystem to give the French pharma giant an edge
Sanofi is developing custom tools and reimagining AI workflows, rather than rely on agentic products sold by SaaS vendors.
Sanofi: Information concerning the total number of voting rights and shares - April 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g...
Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa
Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa
1 Dirt Cheap Growth Stock to Buy Right Now
Sanofi is generating some solid growth and it trades at an incredibly low valuation.
Sanofi reports ElevAATe trial of efdoralprin alfa meets primary endpoint
Sanofi (SNY) announced data from the global ElevAATe phase 2 study demonstrated superiority of investigational efdoralprin alfa over standard-of-care therapy in achieving and maintaining normalized fu...
Sanofi says rare lung disease drug outperforms standard care in trial
French drugmaker Sanofi said on Monday a trial showed its rare disease therapy was better than standard care in raising levels of a key protein in patients with a genetic form of lung disease.
Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares
Sanofi's Strategic Acquisition of AgomAb Therapeutics NV Shares
Shirley Ballas looks back: ‘I was crying about a breakup, so Mum smacked me round the face’
The Strictly judge and her mum on Shirley’s love of dance, being a single-parent family, and the joy of living together now Born in Wallasey (now Merseyside) in 1960, Shirley Ballas is one of the most...
Sanofi asks to pull diabetes drug out of FDA voucher program, STAT News reports
Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator's new fast-track review program, STAT News reported on Wednesday.
Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven Alpha-1 detection strategies, which will enable earlier patient identification DURHAM, N.C., May 6, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization pow...
This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout
Biotech stock Avalo Therapeutics skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.
Regeneron, Sanofi present results from Dupixent Phase 4 trial
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented results from the REMODEL Phase 4 trial demonstrating that Dupixent showed significant and clinically meaningful improvements in both esophag...
Sanofi invests C$294M to expand AI Center of Excellence in Toronto
Sanofi (SNY) is expanding its global Artificial Intelligence Centre of Excellence in Toronto, deepening its investment in Ontario and growing AI talent to develop and manufacture medicines and vaccine...
Sanofi downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Sanofi (SNY) to Equal Weight from Overweight with a price target of $52, down from $55. Q1 results support upside to 2026 numbers and scope for a…
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on Apri...
Giants Costco, Sanofi, and SAP Raise Dividends by Over 10%
Several stocks with market capitalizations above $100 billion just made notable dividend announcements. These names are among the largest in their respective industries, and despite widely differing p...